Optimizing therapy early in multiple sclerosis: An evidence-based view
Open Access
- 16 July 2015
- journal article
- review article
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 4 (5), 460-469
- https://doi.org/10.1016/j.msard.2015.07.007
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma AG
This publication has 100 references indexed in Scilit:
- JC virus antibody status underestimates infection ratesAnnals of Neurology, 2013
- Inflammatory Cortical Demyelination in Early Multiple SclerosisNew England Journal of Medicine, 2011
- Multiple sclerosis: current treatment algorithmsCurrent Opinion in Neurology, 2011
- Mechanisms of neuronal dysfunction and degeneration in multiple sclerosisProgress in Neurobiology, 2010
- Evolving expectations around early management of multiple sclerosisTherapeutic Advances in Neurological Disorders, 2010
- Evidence for a two-stage disability progression in multiple sclerosisBrain, 2010
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisThe Lancet Neurology, 2010
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMultiple Sclerosis Journal, 2010
- MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2007